Here we report on the most recent updates on experimental drugs successfully em-
ployed in the treatment of the disease caused by SARS-CoV-2 coronavirus, also referred to as
COVID-19 (COronaVIrus Disease 19). In particular, several cases of recovered patients have
been reported after being treated with lopinavir/ritonavir (which is widely used to treat human
immunodeficiency virus (HIV) infection) in combination with the anti-flu drug oseltamivir. In
addition, remdesivir, which has been previously administered to Ebola virus patients, has also
proven effective in the U.S. against coronavirus, while antimalarial chloroquine and hydroxy-
chloroquine, favipiravir and co-administered darunavir and umifenovir (in patient therapies)
were also recently recorded as having anti-SARS-CoV-2 effects. Since the recoveries/deaths
ratio in the last weeks significantly increased, especially in China, it is clear that the experi-
mental antiviral therapy, together with the availability of intensive care unit beds in hospitals
and rigorous government control measures, all play an important role in dealing with this vi-
rus. This also stresses the urgent need for the scientific community to devote its efforts to the
development of other more specific antiviral strategies.
Keywords: SARS-CoV-2, Coronavirus, COVID-19, antiviral drugs, hydroxychloroquine, remdesivir, favipiravir, lopinavir, ritonavir.
Rights & PermissionsPrintExport